Technical Analysis for PRPO - Precipio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical PRPO trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Wide Bands | Range Expansion | -5.61% | |
| Oversold Stochastic | Weakness | -5.61% | |
| Pocket Pivot | Bullish Swing Setup | -9.76% | |
| Lower Bollinger Band Walk | Weakness | -9.76% | |
| Wide Bands | Range Expansion | -9.76% | |
| Oversold Stochastic | Weakness | -9.76% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Lower Bollinger Band Support | about 8 hours ago |
| 2x Volume Pace | about 10 hours ago |
| 1.5x Volume Pace | about 10 hours ago |
| Down 5% | about 10 hours ago |
| Down 3% | about 10 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/12/2021
Precipio, Inc. Description
Precipio, Inc., formerly Transgenomic, Inc., is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment. The Company is engaged in the provision of its Multiplexed ICE COLD-PCR (MX-ICP) product to the clinical market, enabling the use of blood and other bodily fluids for diagnosis, monitoring and treatment of cancer. MX-ICP amplifies the ability to detect genetic mutations by approximately 100 to 400 fold. MX-ICP is validated internally on sequencing platforms, including Sanger, Next Gen Sequencing and Digital polymerase chain reaction (PCR). Its laboratory in Omaha, Nebraska is focused on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted.
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biotechnology Cancer Biology Diseases Natural Sciences Treatment Of Cancer Molecular Biology Multiplex Genomics Research Services Omaha Molecular Diagnostics Laboratory Services Analytical Services Laboratory Techniques Polymerase Chain Reaction Personalized Medicine Digital Polymerase Chain Reaction Pharmacogenomics
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.0 |
| 52 Week Low | 0.55 |
| Average Volume | 626,937 |
| 200-Day Moving Average | 2.35 |
| 50-Day Moving Average | 2.59 |
| 20-Day Moving Average | 2.22 |
| 10-Day Moving Average | 2.08 |
| Average True Range | 0.19 |
| ADX | 17.92 |
| +DI | 13.52 |
| -DI | 29.09 |
| Chandelier Exit (Long, 3 ATRs ) | 2.16 |
| Chandelier Exit (Short, 3 ATRs ) | 2.35 |
| Upper Bollinger Band | 2.60 |
| Lower Bollinger Band | 1.84 |
| Percent B (%b) | 0.01 |
| BandWidth | 34.23 |
| MACD Line | -0.16 |
| MACD Signal Line | -0.13 |
| MACD Histogram | -0.025 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.10 | ||||
| Resistance 3 (R3) | 2.10 | 2.02 | 2.06 | ||
| Resistance 2 (R2) | 2.02 | 1.95 | 2.02 | 2.04 | |
| Resistance 1 (R1) | 1.93 | 1.92 | 1.89 | 1.93 | 2.03 |
| Pivot Point | 1.85 | 1.85 | 1.83 | 1.85 | 1.85 |
| Support 1 (S1) | 1.77 | 1.79 | 1.73 | 1.77 | 1.67 |
| Support 2 (S2) | 1.69 | 1.75 | 1.69 | 1.66 | |
| Support 3 (S3) | 1.60 | 1.69 | 1.64 | ||
| Support 4 (S4) | 1.60 |
